Toremifene and tamoxifen for patients with advanced breast cancer:A metaanalysis of randomized controlled trials
AIM:To evaluate the clinical effectiveness and safety of toremifene ( TOR ) versus tamoxifen (TAM ) for patients with advanced breast cancer. METHODS: This study retrieved relevant randomized controlled trials in PubMed,EMB ASE,Cochrane Library,Chinese Biomedical Literature Database,Chinese Scientific Journal Full-text Database,and Chinese Journal Full-text Database up to June 2008. According to the handbook 4. 2. 6 of Cochrane collaborate,two reviewers assessed the quality of included trials and extracted data independently. The RevMan 4. 2. 10 software was used for Meta-analysis,relative risk( RR) was used as statistical index for numeration data and weighted mean difference (WMD) was used for measurement data. RESULTS: Ten studies were ineiuded(3680 patients). Meta-analysis showed no statistical difference between the 2 groups in 1 and 3-year overall survival rate,but statistical difference was observed in 5-year overall survival rate. The pooled RR and 95% CI were respectively 1. 00 (0.97,1.03),1.04(0.98,1.09) and 1.06(1.01,1.12). No statistical difference was found between the 2 groups in 1 and 3-year disease-free survival rate but statistical difference was observed in 5-year disease-free survival rate. The pooled RR and 95% CI were respectively 1.00(0.98,1.02),1.05(1.00,1.10),and 1.08( 1. 02,1. 15). No statistical difference was found between the 2 groups in complete response,partial response and objective response. The pooled RR and 95% CI were respectively 1. 41 (0.90,2.22),0.91(0.71,1. 17) and 0.97(0.82,1.14). Adverse reactions in TOR group were lower than those in TAM group,and the quality of life was similar in the 2 groups. CONCLUSION: The results suggest that TOR has better effectiveness and safety than TAM in improving the long-term survival rate for patients with advanced breast cancer.
breast neoplasmsendocrine therapyTamoxifenToremifenesystematic review
NETL
NSTL
万方数据
维普
